This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
It uses Creative Commons licenses, such as the Creative NonCommercial Attribution License and the Creative Content Attribution License.
It is licensed under a Creative Commons License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
For permission to republish, please contact the Creative Commision ([email protected]).
To access the full article, register or login.
This article is part of a series.
See: Viral keratoidosis and keratoidosis (http: //news.yahoo.com/news/kratom-sucks-medical-benefits-health-news/article_f8c6dd8e-c966-4c85-a2cd-9b5b1f1f8e9e.html) Kratom has been touted as a potential cure for viral keratopathy, a serious inflammatory condition that can lead to pain, swelling, and swelling-related side effects.
It can be used for cough, congestion, diarrhea, and even as an alternative to opioid painkillers and opiate withdrawal medication.
However, many patients in Colombia have reported that the drug is causing keratotic conjunctiva and keratoacromia, or pink eyes.
It’s possible that the condition can be triggered by consuming the drug, which is also commonly known as kratom, which contains mitragynine alkaloids, such in powder form, as well as the psychoactive compound mitragine.
The cause of viral keratoids is still unclear, but scientists have suspected it might be related to the presence of mitragins in kratom.
A recent study published in the journal PLoS ONE has found that exposure to kratom can trigger keratogenic effects in a mouse model of viral cervical keratomas.
The authors found that mice exposed to kampunga, the active ingredient of kratom and commonly known to induce viral keratalosis, developed the condition within 24 hours after drinking a mixture containing mitragin and the anti-inflammatory compound salicylic acid.
The compound also affected immune system and neurogenesis in the animals.
In a second study, the researchers showed that the compound affected immune cells in the dorsal root ganglion of mice by interfering with the expression of the nuclear receptor for NF-kB.
This receptor is a key part of the immune system, which can be damaged by the immune cells’ activation.
They also found that the effect of kamponga on the NF-κB pathway is triggered by chronic exposure to the compound, which in turn is blocked by a cannabinoid receptor antagonist, WIN55,212-2.
These results indicate that the mitraginosin alkaloid compound mitroprion, which has been shown to be a neuroprotective compound in animal models of viral diseases, could potentially act as a novel therapeutic target in viral keratosclerosis.
Kampungas high levels of mitroprotective compounds are known to protect against several types of infections and inflammation.
This is likely why the researchers chose to test mitroprogenitor cells (a type of stem cells) to examine the effects of mitroprogenitizing compounds, a type of synthetic compound that is known to regulate gene expression in the immune and brain systems.